Serial acquirer of life science companies. Potential to grow EBITA at >30% p.a. including M&A. We initiate with BUY and TP SEK 23, implying ~70% upside.


Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
M&A potential adds up
ADDvise Group AB Class A (ADDV.A:OME) | 0 0 0.0%
- Published:
09 Feb 2024 -
Author:
ABGSC Healthcare Research | Sten Gustafsson -
Pages:
39 -
Serial acquirer of life science companies. Potential to grow EBITA at >30% p.a. including M&A. We initiate with BUY and TP SEK 23, implying ~70% upside.